Company: PRTA
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001559053-25-000009
Chunk: 157

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 157
---
445 — 21,457 Issuance of ordinary shares upon vesting of restricted stock units5,750 — — — — Issuance of ordinary shares in public offering, net of issuance costs of $1.4 million395,096 4 20,905 — 20,909 Issuance of ordinary shares under the at-the-market offering program, net of issuance costs of $153 thousand42,361 — 3,071 — 3,071 Net loss— — — (147,028)(147,028)Balances at December 31, 202353,682,117 537 1,540,859 (980,031)561,365 Share-based compensation45,964 45,964 Issuance of ordinary shares upon exercise of stock options125,615 1 1,906 1,907 Issuance of ordinary shares upon vesting of restricted stock units19,250 — — — Net loss(122,310)(122,310)Balances at December 31, 202453,826,982 $538 $1,588,729 $(1,102,341)$486,926 

See accompanying Notes to Consolidated Financial Statements.

81

Notes to the Consolidated Financial Statements

1.Organization

Description of BusinessProthena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company’s wholly-owned programs include birtamimab for the potential treatment of AL amyloidosis, and a portfolio of programs for the potential treatment of Alzheimer’s disease including PRX012, which targets amyloid beta (Aβ), and PRX123, a novel dual Aβ-tau vaccine. The Company’s partnered programs include prasinezumab for the potential treatment of Parkinson’s disease and other related synucleinopathies that targets alpha-synuclein in collaboration with Roche. In addition, we have partnered BMS